(866) 280-3417 Call for Free Case Review

Glyxambi Lawsuit Lawyer

Glyxambi Lawsuits: Kidney Failure & Diabetic Ketoacidosis

Commonly asked questions about Glyxambi (empagliflozin/linagliptin):

What Is Glyxambi?

Glyxambi (empagliflozin/linagliptin) is a drug of the gliflozin class used to treat Type 2 diabetes. It was developed by Boehringer Ingelheim. The U.S. Food and Drug Administration approved Glyxambi in 2015 for glycemic control, along with diet and exercise, in adults with Type 2 diabetes.

What Are The Side Effects Of Glyxambi?

The FDA reports that the most common side effects of Glyxambi are genital fungal infections and urinary tract infections. Other side effects may include:

CoughNausea
DiarrheaJoint Pain
Increased UrinationRunny or Stuffy Nose
Common Cold SymptomsUpper Respiratory Tract Infections

Are There Any Glyxambi Lawsuits or Recalls?

As Glyxambi is a new drug, there are no recalls or lawsuits yet. However, The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines, which include Glyxambi, may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization.

The FDA says that patients should pay close attention for any signs of ketoacidosis and seek medical attention immediately if they experience symptoms such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness.

Glyxambi is an SGLT2 inhibitor, which is a class of prescription medicines for use with diet and exercise to lower blood sugar in adults with type 2 diabetes. SGLT2 inhibitors lower blood sugar by causing the kidneys to remove sugar from the body through the urine.

What Makes Me Eligible for an Glyxambi Lawsuit?

The manufacturers of SGLT2 Inhibitors have been the subject of litigation because of the side effects caused by their drugs.

The national Invokana lawsuit alleges that the manufacturers and marketers of SGLT2 Inhibitors failed to warn patients and physicians of the increased risks of kidney failure, myocardial infarction (heart attacks), other cardiovascular issues, and ketoacidosis.

The lawsuit states that if the manufacturers and marketers had properly warned of the risks, patients would have been prescribed and taken a substitute medication for their diabetes and would have had their health monitored on a more routine basis for potential signs of heart issues, renal impairment, and high level of ketones.

If you suffered severe complications from taking an SGLT2 Inhibitor, you may be entitled to compensation. Below is the criteria required to file an SGLT2 Inhibitor lawsuit:

  • Patient has taken Invokana, Invokamet, Farxiga, Glyxambi, Jardiance, or Xigduo XR and suffered one or more of the following:
    • Kidney failure
    • Diabetic Ketoacidosis
    • Heart attack
    • Stroke
    • Death
    • Dehydration requiring hospitalization
    • Bone fracture
    • Amputation

Our No-Fee Promise on Glyxambi Cases

You can afford to have our great team of Glyxambi lawyers on your side. If you choose us, it literally costs you nothing to get started. We promise you in writing:

  • No money to get started
  • We pay all case costs and expenses
  • No legal fees whatsoever unless you receive a Glyxambi settlement
  • Phone calls are always free

We will listen to your story and answer any questions you have. If you have claim, we will begin work immediately.

How Do I Start A Glyxambi Claim?

Our Glyxambi drug lawyers will help you file your lawsuit. To get started, you can:

  1. Submit the Free Case Review Box on this page, or
  2. Call 866-280-3417 any time of day to tell us about your case.

We will listen to your story and answer your questions. If you have a claim, we will start immediately.

WARNING: There are strict time deadlines for filing Glyxambi lawsuit claims.

Glyxambi Kidney Failure Lawyer Review

Drug Lawsuit Source Client Review
Review Date
Reviewed
Prescription Drug Lawyer
Client Rating
51star1star1star1star1star

Glyxambi News – Lawsuits, Settlements, Information